Since our founding in 2007,  Torreya has become a leading financial advisor on life sciences transactions around the globe and across life sciences sectors and therapeutic areas. We have closed over $100 billion worth of deals across nearly 250 assignments.

FILTER BY:

Neuland Laboratories
Acquisition of
API facility from
Arch Pharma
Undisclosed
December 2017
Crown Laboratories
Sale of
majority equity stake to
Hildred
Undisclosed
December 2017
Zylera
Sale to
Cerecor
Up to $34 million
November 2017
CombiMatrix
Merger with
Invitae Corporation
$34.9 million
November 2017
XOMA
License of
Gevokizumab and
certain associated IP to
Novartis
$31 million upfront
August 2017
Sandoz
Sale of
generics portfolio to
FosunPharma
$18 million
August 2017
Essential Pharmaceuticals
Asset sale to
Accord
Undisclosed
July 2017
Sandoz
Sale of selected
generic brands to
Samara Capital
Undisclosed
June 2017
Alphora Research
Sale of company to
Eurofins Scientific
Undisclosed
June 2017
Sawai
Acquisition of
generics business of
Upsher-Smith
$1.05 billion
June 2017
Selexis
Company sale to
JSR Life Sciences
Undisclosed
June 2017
Durect
License of US rights to Posimir® to
Sandoz
$293 million
May 2017
Neuland Laboratories
Sale of stake of
InvAscent
$35 million
Joint Sell-Side Advisor
May 2017
Clarus Ventures
Acquisition of phase III royalty interest
Undisclosed
Undisclosed
May 2017
Cipher
Sale of US dermatology business to
EPI
$13.6 million
May 2017
Sandoz
Sale of India women's health business to
Torrent Pharma
Undisclosed
April 2017
Mallinckrodt Pharmaceuticals
Sale of
Intrathecal business to
Piramal
$203 million
March 2017
Wafergen Biosystems
Company sale to
Takara
$35.9 million
March 2017
MainPointe Pharma
Acquired SLO Niacin® from
Upsher-Smith
Undisclosed
March 2017
MainPointe Pharma
Licensed Nexafed® from
Acura Pharma
Undisclosed
March 2017
Assembly Biosciences
Microbiome partnership with
Allergan
$2.6 billion
($50 million upfront)
January 2017
XOMA
Sale of royalties to
Healthcare Royalty Partners
$22 million
December 2016
Opiant Pharmaceuticals
Sale of royalties to
SWK Holdings
$17.5 million
December 2016
Apollo Endosurgery
Merger with
Lpath
$251 million
December 2016
Conatus Pharmaceuticals
Collaboration agreement for Emricasan with
Novartis
$50 million upfront
December 2016
Atopix
Company sale to
Chiesi
> €75 million
November 2016
Rubicon Research
Sale of equity stake to
Everstone Group
$33 million
November 2016
Female Health
Merger with
Aspen Park
Undisclosed
October 2016
SciDose
Partial sale of royalty
and milestones
Undisclosed
$40 million
September 2016
IntelgenX
Partial royalty and milestone sale to
SWK Holdings
$6 million
August 2016
Academic Investor
Sale of
phase II enzyme replacement royalty
Undisclosed
Undisclosed
August 2016
Topix Pharmaceuticals
Sale of majority stake to
New Mountain Capital
Undisclosed
July 2016
Cardiome
Licensing of
Dalbavancin from
Allergan
$13 million upfront
May 2016
DBV Technologies
License of
milk allergy product to
Nestle
€100 million
May 2016
Plexcera Therapeutics
Sale and contribution of orphan disease asset to
Roivant Sciences
Undisclosed
May 2016
Acerus Pharma
US license agreement
for NATESTO® to
Aytu BioScience
Up to $45.5 million
($8 million upfront)
April 2016
Eisai
Sale of Akarx to
PBM Capital Group
Undisclosed
March 2016
Hikma Pharmaceuticals
Sale of abbreviated
new drug applications
Undisclosed
Undisclosed
February 2016
H2-Pharma
Sale of assets to
ANI Pharmaceuticals
$10 million
February 2016
HealthCare Royalty Partners
Royalty-backed
acquisition financing
for undisclosed
spec pharma
Undisclosed
$100 million
February 2016
Cambrooke Therapeutics
Preferred equity investment
undisclosed
$7 million
January 2016
PhosImmune
Sale to
Agenus
Up to $45 million
($16 million upfront)
December 2015
VistaPharm
Company sale to
Warburg Pincus
$100+ million
December 2015
Midatech Pharma
Acquisition of
Dara Biosciences
Up to $30 million
December 2015
Amerigen
Senior term loan
Undisclosed
$15 million
December 2015
XOMA
Sale of
biologics manufacturing
facilities to
Agenus
$5 million in cash +
$1 million in stock
November 2015
IGI Laboratories
Acquisition of
Alveda Pharmaceuticals
CAD $47 million
October 2015
XOMA
License of global rights
for Anti-TGF-beta
antibody program to
Novartis
Up to $517 million
October 2015
Crown Laboratories
Debt financing from
Hayfin Advisors
$20 million
September 2015
cCam Biotherapeutics
Sale to
Merck
Up to $605 million
July 2015
Teva
Sale of abbreviated
new drug application
portfolio to
ANI Pharmaceuticals
$25 million +
profit share
July 2015
ProSolus
Sale to
Mission Pharmacal
Undisclosed
June 2015
arGEN-X
License of preclinical
derm antibody to
LEO Pharma
Up to €105 million
May 2015
Ipsen
Acquisition of
OctreoPharm Sciences
Up to €50 million
May 2015
Sandoz
Sale of
Zonalon® to
Renaissance Pharma
Undisclosed
March 2015
Phenex
Sale of FXR program to
Gilead
Up to $470 million
January 2015
Lightlake Therapeutics
License of naloxone
opioid overdose reversal treatment to
Adapt Pharma
$55+ million
December 2014
Aseptix Health Sciences
License of antimicrobial technology to
Ecolab
Undisclosed
December 2014
Flamel Technologies
Sale of Pessac plant to
Recipharm AB
Up to €22 million
November 2014
Sandoz
Divestiture of
certain abbreviated
new drug applications to
IDT Australia
Up to $18 million
October 2014
PDI
Acquisition of
Redpath Integrated Pathology
Up to $35 million
October 2014
PDI
Acquisition financing
from
SWK Holdings
$20 million
October 2014
Probiodrug
Financial advisor
on IPO
Undisclosed
$30 million
October 2014
CureTech
License of Pidilizumab to
Medivation
Up to $335 million
with royalty
October 2014
DBV Technologies
Global offering advisory
Undisclosed
$133 million
October 2014
ABT Molecular Imaging
Synthetic royalty
financing from
SWK Holdings
$10 million
October 2014
Innovative Therapies
Sale to
Cardinal Health
$65 million
September 2014
Trimel Pharmaceuticals
Acquisition of
Canadian rights to
Estrace® from
Shire
$41 million
July 2014
Trimel Pharmaceuticals
Loan from
MidCap Financial
$25 million
July 2014
Ventrus Biosciences
Merger with
Assembly Pharmaceuticals
$24 million
July 2014
Chelsea Therapeutics
Sale to
Lundbeck
$658 million
June 2014
Fibrotech
Sale to
Shire
$75 million upfront + milestones
May 2014
Concordia International Corp.
Acquisition of
Donnatal® from
Revive Pharmaceuticals
$328 million
May 2014
Compugen
Financial advisor on
follow-on offering
Undisclosed
$72.5 million
February 2014
Zila
Sale of substantially
all assets to
DenMat
Undisclosed
February 2014
4-Antibody AG
Sale to
Agenus
$40+ million with
$10 million upfront
January 2014
Teva
Sale of 31 abbreviated
new drug applications to
ANI Pharmaceuticals
$12.5 million +
profit share
December 2013
Pinnacle Biologics
Sale to
Concordia Healthcare
Undisclosed
December 2013
Almac
License of chemotherapy benefit test for high risk breast cancer to
Genomic Health
$9 million + milestones and royalties
November 2013
Correvio
Sale to
Cardiome
19.9% of shares +
$12 million
November 2013
DBV Technologies
Financial advisor in
private placement
Undisclosed
€29.9 million
November 2013
Shionogi
Sale of Naprelan® to
Alvogen
Undisclosed
November 2013
Canterbury Laboratories
Merger into
Restorgenex
Undisclosed
September 2013
Compugen
Advisor on oncology partnership with
Bayer
$550 million with
$10 million upfront
August 2013
Inviragen
Sale of
vaccine company to
Takeda
$250 million with
$35 million upfront
May 2013
Shionogi
Divestiture of three pediatric drugs to
Concordia Pharmaceuticals
$28.7 million
May 2013
Selexis
Sale of basket of
royalties to
Ligand
$6 million upfront
April 2013
Clinigen
Acquisition of EU rights
to Vibativ® from
Theravance
$5 million + royalties
March 2013
Molecular Insight
Sale for up to
$106 million to
Progenics
$12 million +
milestones
January 2013
SpePharm
Collaboration with
Norgine
Undisclosed
December 2012
GTx
Sale of Fareston® to
Prostrakan/Kyowa Hakko Kirin
$21.7 million
October 2012
Xanodyne
Sale of
Amicar® rights to
Versapharm
Undisclosed
August 2012
Shionogi
Divestiture of
Cuvposa® to
Merz
Undisclosed
August 2012
Xanodyne
Sale of
Roxicodone® to
Covidien
Undisclosed
August 2012
Xanodyne
Sale of Zipsor® to
Depomed
Undisclosed
June 2012
Hedge Fund
Structured debt transaction linked to
three pharma royalties
Pharmakon
$65 million
December 2011
Amorcyte
Sale to
Neostem
$10 million +
milestones
October 2011
Xanodyne
Sale of
prenatal vitamin
franchise
Undisclosed
Undisclosed
October 2011
Ventrus Biosciences
Financial advisor in
follow-on financing
for GI company
Undisclosed
Undisclosed
July 2011
Aegera Therapeutics
Sale of Canadian biotechnology
company to
Pharmascience
Undisclosed
May 2011
Xanodyne
Co-promotion for
Zipsor®
Medimetriks
Undisclosed
May 2011
Hedge Fund
Sale of
royalties for Cubicin®
and Lexiscan® to
Royalty Pharma
$487 million
April 2011
Lpath
Advisor in
iSonep license to
Pfizer
$500 million with
$14 million upfront
December 2010
Quinnova
Sale of dermatology specialty pharma
business to
Amneal
Undisclosed
December 2010
Three Rivers Pharma
Sale to
Kadmon
$100+ million
October 2010
GTCR
Advisor in the acquisition of six products from
UCB
Undisclosed
July 2010
Columbia Labs
Sale of
Crinone® & Prochieve® product lines and
shares to
Watson
$92.5 million with
$47 million upfront
July 2010
DNP
Acquisition of
Thorne Research
$40 million +
milestones
June 2010
Shareholder Group
Advisor to Genentech
major shareholder
in sale to
Roche
$46 billion
March 2009
AGI Dermatics
Sale to
Estée Lauder
Undisclosed
September 2008
ProEthic Pharma
Sale to
Kowa Pharmaceuticals
Undisclosed
April 2008